I have been following Achillion Pharmaceuticals (ACHN) since October, 2012. My first article (click here) was an in-depth look at the company and the exciting developments of their drug pipeline, to treat, and potentially cure, Hepatitis C.
The stock has bounced around since that first article, and the movement has been rather interesting, but certainly not unusual in the small cap bio-tech world.
The stock was highest when I first wrote about it, and with subsequent follow up articles as well. As you can see from this chart, the most recent upward move has coincided with the recent presentations that the company has made during the month of May.
I outlined these presentation dates in ...
Only subscribers can access this article, which is part of the PRO research library covering 3,592 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: